vs
Assertio Holdings, Inc.（ASRT）与Castellum, Inc.（CTM）财务数据对比。点击上方公司名可切换其他公司
Assertio Holdings, Inc.的季度营收约是Castellum, Inc.的1.1倍（$13.5M vs $12.6M），Castellum, Inc.同比增速更快（21.9% vs -57.9%），过去两年Castellum, Inc.的营收复合增速更高（5.3% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
Castellum, Inc.是一家总部位于美国的网络安全与信息技术服务提供商，服务覆盖国防政府机构、公共部门及商业企业客户，提供威胁检测、数据保护、云安全及托管IT解决方案，助力客户防范网络风险、保护核心数字资产。
ASRT vs CTM — 直观对比
营收规模更大
ASRT
是对方的1.1倍
$12.6M
营收增速更快
CTM
高出79.9%
-57.9%
两年增速更快
CTM
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $12.6M |
| 净利润 | — | $-1.3M |
| 毛利率 | — | 33.9% |
| 营业利润率 | -86.7% | -11.1% |
| 净利率 | — | -10.5% |
| 营收同比 | -57.9% | 21.9% |
| 净利润同比 | — | 51.8% |
| 每股收益（稀释后） | $-4.54 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTCTM
| Q4 25 | $13.5M | $12.6M | ||
| Q3 25 | $49.5M | $14.6M | ||
| Q2 25 | $29.2M | $14.0M | ||
| Q1 25 | $26.5M | $11.7M | ||
| Q4 24 | $32.2M | $10.3M | ||
| Q3 24 | $29.2M | $11.6M | ||
| Q2 24 | $31.1M | $11.5M | ||
| Q1 24 | $32.4M | $11.3M |
净利润ASRTCTM
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $11.4M | $415.4K | ||
| Q2 25 | $-16.4M | $-322.1K | ||
| Q1 25 | $-13.5M | $-1.2M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | $-2.9M | $-1.3M | ||
| Q2 24 | $-3.7M | $-1.8M | ||
| Q1 24 | $-4.5M | $-4.1M |
毛利率ASRTCTM
| Q4 25 | — | 33.9% | ||
| Q3 25 | — | 37.6% | ||
| Q2 25 | — | 36.1% | ||
| Q1 25 | — | 39.0% | ||
| Q4 24 | — | 40.0% | ||
| Q3 24 | — | 42.7% | ||
| Q2 24 | — | 40.6% | ||
| Q1 24 | — | 39.8% |
营业利润率ASRTCTM
| Q4 25 | -86.7% | -11.1% | ||
| Q3 25 | 23.2% | 3.0% | ||
| Q2 25 | -27.5% | -2.7% | ||
| Q1 25 | -50.0% | -12.7% | ||
| Q4 24 | -41.9% | -15.7% | ||
| Q3 24 | -10.4% | -11.9% | ||
| Q2 24 | -11.6% | -13.6% | ||
| Q1 24 | -13.4% | -23.6% |
净利率ASRTCTM
| Q4 25 | — | -10.5% | ||
| Q3 25 | 23.1% | 2.8% | ||
| Q2 25 | -56.0% | -2.3% | ||
| Q1 25 | -51.1% | -10.0% | ||
| Q4 24 | — | -26.6% | ||
| Q3 24 | -10.0% | -11.0% | ||
| Q2 24 | -11.8% | -16.0% | ||
| Q1 24 | -13.9% | -36.3% |
每股收益（稀释后）ASRTCTM
| Q4 25 | $-4.54 | $-0.02 | ||
| Q3 25 | $0.11 | $0.00 | ||
| Q2 25 | $-0.17 | $0.00 | ||
| Q1 25 | $-0.14 | $-0.01 | ||
| Q4 24 | $-3.28 | $-0.05 | ||
| Q3 24 | $-0.03 | $-0.02 | ||
| Q2 24 | $-0.04 | $-0.03 | ||
| Q1 24 | $-0.05 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $94.0M | $35.8M |
| 总资产 | $267.0M | $41.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASRTCTM
| Q4 25 | $63.4M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $98.2M | — | ||
| Q1 25 | $87.3M | — | ||
| Q4 24 | $100.1M | — | ||
| Q3 24 | $88.6M | — | ||
| Q2 24 | $88.4M | — | ||
| Q1 24 | $80.7M | — |
总债务ASRTCTM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.0M | ||
| Q3 24 | — | $8.3M | ||
| Q2 24 | — | $8.7M | ||
| Q1 24 | $38.6M | $9.0M |
股东权益ASRTCTM
| Q4 25 | $94.0M | $35.8M | ||
| Q3 25 | $105.8M | $36.7M | ||
| Q2 25 | $93.3M | $31.8M | ||
| Q1 25 | $108.5M | $26.1M | ||
| Q4 24 | $121.1M | $20.2M | ||
| Q3 24 | $130.5M | $12.0M | ||
| Q2 24 | $132.2M | $12.1M | ||
| Q1 24 | $134.5M | $12.8M |
总资产ASRTCTM
| Q4 25 | $267.0M | $41.9M | ||
| Q3 25 | $319.8M | $46.3M | ||
| Q2 25 | $273.8M | $43.4M | ||
| Q1 25 | $286.4M | $41.1M | ||
| Q4 24 | $284.7M | $37.8M | ||
| Q3 24 | $276.0M | $28.8M | ||
| Q2 24 | $279.4M | $29.5M | ||
| Q1 24 | $282.0M | $30.5M |
负债/权益比ASRTCTM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | 0.29× | 0.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $-661.7K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASRTCTM
| Q4 25 | $-30.0M | $-661.7K | ||
| Q3 25 | $-4.8M | $1.0M | ||
| Q2 25 | $19.1M | $214.2K | ||
| Q1 25 | $-12.5M | $-2.5M | ||
| Q4 24 | $11.5M | $-394.4K | ||
| Q3 24 | $-35.0K | $742.2K | ||
| Q2 24 | $7.4M | $748.6K | ||
| Q1 24 | $7.5M | $23.7K |
自由现金流ASRTCTM
| Q4 25 | — | — | ||
| Q3 25 | — | $957.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $738.9K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ASRTCTM
| Q4 25 | — | — | ||
| Q3 25 | — | 6.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ASRTCTM
| Q4 25 | — | — | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率ASRTCTM
| Q4 25 | — | — | ||
| Q3 25 | -0.42× | 2.41× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
CTM
暂无分部数据
